Dr. P. Keiser and colleagues from the Southwestern Medical center in Dallas reported on their findings in an open label trial comparing ddI given once or twice a day. The patients were nucleoside analog experienced and had median viral loads greater than 100,000 copies/ml. Changes in viral load were comparable between the two groups at about one half log at 8 weeks. One person in the bid group developed pancreatitis, and 3 qd patients complained of gi intolerance and stopped medication. 5/8 patients in each arm were judged to be adherent to the study regimen. In summary, the once daily dosing of ddI seemed comparable to the twice daily regimen in terms of antiviral activity and tolerability in this preliminary study.